Literature DB >> 29392586

Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Sandra Sirrs1,2, Fady Hannah-Shmouni3, Stephen Nantel4,5, James Neuberger6, Eric M Yoshida7.   

Abstract

Transplantation is an established disease modifying therapy in selected children with certain inherited metabolic diseases (IMDs). Transplantation of hematopoietic stem cells or solid organs can be used to partially correct the underlying metabolic defect, address life threatening disease manifestations (such as neutropenia) or correct organ failure caused by the disease process. Much less information is available on the use of transplantation in adults with IMDs. Transplantation is indicated for the same IMDs in adults as in children. Despite similar disease specific indications, the actual spectrum of diseases for which transplantation is used differs between these age groups and this is partly related to the natural history of disease. There are diseases (such as urea cycle defects and X-linked adrenoleukodystrophy) for which transplantation is recommended for selected symptomatic patients as a treatment strategy in both adults and children. In those diseases, the frequency with which transplantation is used in adults is lower than in children and this may be related in part to a reduced awareness of transplantation as a treatment strategy amongst adult clinicians as well as limited donor availability and allocation policies which may disadvantage adult patients with IMDs. Risks of transplantation and disease-specific prognostic factors influencing outcomes also differ with age. We review the use of transplantation as a disease modifying strategy in adults focusing on how this differs from use in children to highlight areas for future research.

Entities:  

Keywords:  Adult; Hematopoietic stem cell transplantation; Inherited metabolic diseases; Liver transplantation; Urea cycle defects; X-linked adrenoleukodystrophy

Mesh:

Year:  2018        PMID: 29392586     DOI: 10.1007/s10545-018-0141-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  79 in total

Review 1.  Management of ornithine transcarbamylase deficiency in pregnancy.

Authors:  Hector Mendez-Figueroa; Kerri Lamance; V Reid Sutton; Kjersti Aagaard-Tillery; Ignatia Van den Veyver
Journal:  Am J Perinatol       Date:  2010-05-10       Impact factor: 1.862

2.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR).

Authors:  René Adam; Vincent Karam; Valérie Delvart; John O'Grady; Darius Mirza; Jurgen Klempnauer; Denis Castaing; Peter Neuhaus; Neville Jamieson; Mauro Salizzoni; Stephen Pollard; Jan Lerut; Andreas Paul; Juan Carlos Garcia-Valdecasas; Fernando San Juan Rodríguez; Andrew Burroughs
Journal:  J Hepatol       Date:  2012-05-16       Impact factor: 25.083

3.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

4.  Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy.

Authors:  Marlijn de Beer; Marc Engelen; Björn M van Geel
Journal:  Neurology       Date:  2014-11-05       Impact factor: 9.910

5.  Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation.

Authors:  Y Yamada; K Kato; K Sukegawa; S Tomatsu; S Fukuda; S Emura; S Kojima; T Matsuyama; W S Sly; N Kondo; T Orii
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

Review 6.  Chronic graft-versus-host disease (GVHD) in children.

Authors:  Kristin Baird; Kenneth Cooke; Kirk R Schultz
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

Review 7.  Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University.

Authors:  Daisuke Morioka; Mureo Kasahara; Yasutsugu Takada; Yasumasa Shirouzu; Kaoru Taira; Seisuke Sakamoto; Kenji Uryuhara; Hiroto Egawa; Hiroshi Shimada; Koichi Tanaka
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

8.  Liver transplantation for glycogen storage disease type Ia.

Authors:  Srinevas K Reddy; Stephanie L Austin; Michele Spencer-Manzon; Dwight D Koeberl; Bryan M Clary; Dev M Desai; Alastair D Smith; Priya S Kishnani
Journal:  J Hepatol       Date:  2009-06-17       Impact factor: 25.083

9.  Selection of patients for liver transplantation and allocation of donated livers in the UK.

Authors:  J Neuberger; A Gimson; M Davies; M Akyol; J O'Grady; A Burroughs; M Hudson
Journal:  Gut       Date:  2007-09-25       Impact factor: 23.059

10.  Treatment of Niemann-Pick disease type B by allogeneic bone marrow transplantation.

Authors:  A Vellodi; J R Hobbs; N M O'Donnell; B S Coulter; K Hugh-Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-28
View more
  3 in total

1.  N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia.

Authors:  Yuqi Cui; Lingjuan Liu; Yuan Xiao; Xin Li; Jia Zhang; Xiaoyun Xie; Jie Tian; Chandan K Sen; Xiaoming He; Hong Hao; Zhenguo Liu
Journal:  Eur J Pharmacol       Date:  2020-05-31       Impact factor: 4.432

2.  Concomitant overexpression of triple antioxidant enzymes selectively increases circulating endothelial progenitor cells in mice with limb ischaemia.

Authors:  Lingjuan Liu; Yuqi Cui; Xin Li; Xingyi Que; Yuan Xiao; Chunlin Yang; Jia Zhang; Xiaoyun Xie; Peter J Cowan; Jie Tian; Hong Hao; Zhenguo Liu
Journal:  J Cell Mol Med       Date:  2019-04-11       Impact factor: 5.310

Review 3.  mRNA and gene editing: Late breaking therapies in liver diseases.

Authors:  Nerea Zabaleta; Laura Torella; Nicholas D Weber; Gloria Gonzalez-Aseguinolaza
Journal:  Hepatology       Date:  2022-04-01       Impact factor: 17.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.